CSPC Pharmaceutical Group Limited
1093
Rank in Stocks
#1743
CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is... CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's Republic of China, across Asia, in the Americas, and throughout Europe. The company structures its business activities into three main divisions: Finished Drugs, Bulk Products, and Functional Food and Other ventures. The company's extensive portfolio of finished drugs encompasses treatments for a wide range of conditions. Key offerings include NBP (available as soft capsules and injections) for acute ischemic stroke, and Oulaining (capsules and injections) addressing mild to moderate memory and cognitive impairments. For neurological disorders, Enxi targets adult idiopathic Parkinson's disease. In oncology, Duomeisu treats lymphoma, multiple myeloma, ovarian and breast cancers, alongside other malignant tumors, while Jinyouli aids in preventing chemotherapy-induced leucopenia and infections, and Keaili is prescribed for breast cancer. Further therapeutic areas covered by CSPC include various infections, with products such as Shuluoke, Nuomoling, Weihong, and Xinweihong. Cardiovascular health is addressed by Xuanning for hypertension and Encun to avert atherosclerotic thrombosis events. Qixiao provides relief for upper respiratory tract infections, and diabetes management is supported by Linmeixin and Shuanglexin. Bone health solutions include Gubang and Gubangjia for postmenopausal osteoporosis. Additionally, Gaoshunsong offers relief for a broad spectrum of inflammatory and pain-related conditions, including arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursitis, tenosynovitis, acute gout, dysmenorrhea, toothache, postoperative pain, lower back pain, sprains, strains, and other soft tissue injuries. Other notable products include Debixin for various types of ulcers and Qimaite for acute and chronic pain management. Beyond finished pharmaceuticals, CSPC also supplies active pharmaceutical ingredients (APIs) like antibiotics, vitamin C, and caffeine. The company further diversifies into functional foods, glucose products, and provides healthcare services. Originally established in 1992, the company initially operated under the name China Pharmaceutical Group Limited before adopting its current designation, CSPC Pharmaceutical Group Limited, in March 2013. Its primary corporate office is situated in Shijiazhuang, within the People's Republic of China.
Share Price
$1.06
Market Cap
$12.14B
Change (1 day)
-3.97%
Change (1 year)
-2.20%
Country
CN
Trade CSPC Pharmaceutical Group Limited (1093)
Category
Healthcare
P/E ratio for CSPC Pharmaceutical Group Limited (1093)
P/E ratio as of October 2026 TTM: 10.93
According to CSPC Pharmaceutical Group Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 10.93. At the end of 2024 the company had a P/E ratio of 12.73.
P/E ratio history for CSPC Pharmaceutical Group Limited from 2003 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 10.93 | -57.21% |
| 2025 | 25.55 | 100.66% |
| 2024 | 12.73 | -13.19% |
| 2023 | 14.67 | -6.65% |
| 2022 | 15.71 | -14.46% |
| 2021 | 18.37 | -5.49% |
| 2020 | 19.43 | -37.71% |
| 2019 | 31.20 | 41.73% |
| 2018 | 22.01 | -48.49% |
| 2017 | 42.73 | 63.02% |
| 2016 | 26.21 | -21.86% |
| 2015 | 33.55 | -16.97% |
| 2014 | 40.40 | -8.07% |
| 2013 | 43.95 | 2,247.39% |
| 2012 | 1.87 | -73.39% |
| 2011 | 7.04 | -32.64% |
| 2010 | 10.44 | 35.15% |
| 2009 | 7.73 | 58.22% |
| 2008 | 4.88 | -51.33% |
| 2007 | 10.04 | -92.16% |
| 2006 | 128.04 | 1,028.92% |
| 2005 | 11.34 | -6.45% |
| 2004 | 12.12 | 72.98% |
| 2003 | 7.01 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 40.53 | 270.68% |
US
|
|
| 38.50 | 252.09% |
US
|
|
| 80.21 | 633.65% |
US
|
|
| 116.96 | 969.71% |
US
|
|
| 22.25 | 103.49% |
CH
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.